EBITDA: Income before interest, taxes, depreciation and amortization.
Kyverna Therapeutics, Inc. (KYTX) had EBITDA of $-38.91M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-37.80M |
|
-- |
|
-- |
|
$39.28M |
|
$-39.28M |
|
$1.48M |
|
$-37.80M |
|
$-37.80M |
|
$-37.80M |
|
$-37.80M |
|
$-37.80M |
|
$-37.80M |
|
$-39.28M |
|
|
EBITDA |
$-38.91M |
44.26M |
|
44.26M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$282.95M |
|
$1.55M |
|
$10.87M |
|
$293.83M |
|
$36.49M |
|
$24.74M |
|
$25.06M |
|
$61.55M |
|
$232.28M |
|
$232.28M |
|
$232.28M |
|
60.39M |
|
| Cash Flow Statement Financials | |
$-153.71M |
|
$40.02M |
|
$141.17M |
|
$97.17M |
|
$124.64M |
|
$27.47M |
|
$10.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.75 |
|
-- |
|
-- |
|
0.10 |
|
0.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-153.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.28% |
|
-16.28% |
|
-12.87% |
|
-14.71% |
|
$3.85 |
|
$-3.47 |
|
$-3.47 |
|